公开(公告)号：US20210317480A1

公开(公告)日：2021-10-14

申请号：US17272252

申请日：2019-08-29

Applicant: ShanghaiTech University

Inventor： Jia Liu ,  Biao Jiang ,  Peixiang Ma ,  Guang Yang

IPC: C12N15/90 ,  A61K38/46 ,  A61K38/16 ,  C12N7/00 ,  A61K38/50 ,  A61K31/7088

Abstract: Provided are amino acid sequences capable of binding to and inhibiting a Cas protein's ability to bind to a nucleic acid molecule, thereby inhibiting the Cas protein's function in genome editing. Such Cas protein inhibitors, which can be comprised of a major coat protein (G8P), an extracellular region of the G8P (G8PEX), or a biological equivalent, are useful in improving the specificity of Cas protein-based genome editing procedures.

公开(公告)号：US11492645B2

公开(公告)日：2022-11-08

申请号：US17272252

申请日：2019-08-29

Applicant: ShanghaiTech University

Inventor： Jia Liu ,  Biao Jiang ,  Peixiang Ma ,  Guang Yang

IPC: C12N15/63 ,  A61K31/70 ,  C12N15/90 ,  A61K31/7088 ,  A61K38/16 ,  A61K38/46 ,  A61K38/50 ,  C12N7/00 ,  A01K67/00

Abstract: Provided are amino acid sequences capable of binding to and inhibiting a Cas protein's ability to bind to a nucleic acid molecule, thereby inhibiting the Cas protein's function in genome editing. Such Cas protein inhibitors, which can be comprised of a major coat protein (G8P), an extracellular region of the G8P (G8PEX), or a biological equivalent, are useful in improving the specificity of Cas protein-based genome editing procedures.

公开(公告)号：US20220213176A1

公开(公告)日：2022-07-07

申请号：US17702710

申请日：2022-03-23

Applicant: ShanghaiTech University ,  ShOx Science Limited

Inventor： Peixiang Ma ,  Guang Yang ,  Richard A. Lerner ,  Min Qiang ,  Hou Wang

IPC: C07K16/10 ,  A61P31/14

Abstract: The present disclosure provides human antibodies and fragments thereof having binding specificity to the SARS-CoV-2 spike protein's receptor binding domain (RBD). The antibodies and fragments have strong affinity and potent neutralization ability against the SARS-CoV-2 virus and various mutant forms. Also provided are trimeric antibodies which have further enhanced neutralization capabilities. The antibodies and fragments thus may be used for preventing or treating SARS-CoV-2 viral infection or detecting the presence of the virus in a sample.

公开(公告)号：US11345746B2

公开(公告)日：2022-05-31

申请号：US15781463

申请日：2016-12-14

Applicant: SHANGHAITECH UNIVERSITY

Inventor： Zhihu Qu ,  Guang Yang ,  Fabio Mammano ,  Francesco Zonta

IPC: C07K16/18 ,  A61K39/395 ,  A61K39/00

Abstract: The present invention provides a fully human antibody specifically inhibiting Connexin 26, characterized in that it is a recombinant immunoglobulin having the structure of scFv-Fc, wherein scFv refers to a single-chain antibody comprising a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is SEQ ID NO: 1, the amino acid sequence of the light chain variable region is SEQ ID NO: 2, and Fc refers to constant region. The present invention uses the first 41-56 amino acid sequence of extracellular region of Connexin26 as an antigen, the sequence thereof is KEVWGDEQADFVCNTL. Through the biochemical analysis and immunofluorescence identification of the antibody obtained by single-chain antibody phage display library and screening technology, it was confirmed that the antibody provided by the present invention could specifically recognize Connexin 26 and inhibit its hemichannel activity. Animal experiments show that this antibody significantly inhibits the hemichannel activity of mouse cochlear tissue sections. Therefore, the antibody can be used in the treatment of Connexin mutation associated diseases.

公开(公告)号：US20220332835A1

公开(公告)日：2022-10-20

申请号：US17640309

申请日：2020-09-03

Applicant: ShanghaiTech University

Inventor： Guang Yang ,  Xiaojie Shi

IPC: C07K16/28 ,  A61P35/00

Abstract: Provided are anti-CXCR2 antibodies and antigen-binding fragments thereof. The antibodies or fragments thereof specifically bind to N-terminal, extracellular domain of the CXCR2 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, or any one of SQ ID NO: 7-14, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and inflammatory diseases are also provided.